Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib vs Chemotherapy in ALK+ Advanced NSCLC
NCT00932893Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Sep 2009; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00932893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932893.